January 30, 2024 News by Patricia Inacio, PhD MS treatment Ponvory wins patent protection in US, to run until 2042 The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced. The upcoming patent specifically…
May 23, 2023 News by Andrea Lobo, PhD US patent secured for experimental LPX-TI641 for autoimmune diseases LAPIX Therapeutics has secured a new U.S. patent covering the use of its experimental oral therapy LPX-TI641 as a means to restore immune tolerance in people with autoimmune diseases such as multiple sclerosis (MS). Issued by the U.S. Patent and Trademark Office with the number 11,648,225, the patent…
June 23, 2022 News by Marta Figueiredo, PhD Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely Biogen has secured a new patent in Europe covering the use of its oral therapy TecfideraĀ (dimethyl fumarate) for multiple sclerosis (MS) through 2028, the company announced. Granted by the European Patent Office, patent EP2653873 covers the composition and use of dimethyl fumarate at a dose of 480…
April 1, 2022 News by Lindsey Shapiro, PhD Use of GA Depot in Treating Progressive MS Given US Patent Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, ā…
January 6, 2022 News by Marisa Wexler, MS Generics of Gilenya Not Likely in US for at Least Another Two Years A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the medication’s manufacturer announced. “With this decision, Novartis confirms that it expects no generic versions of Gilenya in the…
October 28, 2021 News by Patricia Inacio, PhD T20K Combo Shows Promise in MS Preclinical Studies New preclinical data continues to support the potential of Cyxoneās investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…
June 18, 2021 News by Marta Figueiredo, PhD Brainstorm Secures NurOwn-associated Patents in Several Markets In the past year, BrainStorm Cell Therapeutics was granted four patents and is waiting for a fifth, already accepted, meant to provide protection for its NurOwn cell therapy and technology in territories around the world. NurOwn is being tested in clinical trials as a potential treatment for…
January 20, 2021 News by Marisa Wexler, MS Clene Awaits US Patent Covering Gold Nanocrystals’ Use in Treating MS Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…
January 18, 2021 News by Marta Figueiredo, PhD Tonix Files for Patent for TNX-1500 to Treat Autoimmune Diseases Tonix Pharmaceuticals has filed a patent application with the World Intellectual Property Organization covering the use of TNX-1500 ā its third-generation anti-CD154 antibody ā for the prevention and treatment of autoimmune diseases, such asĀ multiple sclerosisĀ (MS), and organ transplant rejection. āThere remains a significant need for new treatments with improved…
September 1, 2020 News by Joana Carvalho, PhD SomaCeuticals Acquires Rights to Formula Targeting Lesions in MS SomaCeuticals, a subsidiary of AngioSoma, has acquired exclusive global rights to a patented formula that aims to ease and possibly eliminate signs of neurodegeneration in people with multiple sclerosis (MS). By entering a licensing agreement with 7 to Stand, a Delaware corporation, SomaCeuticals gained access…
August 7, 2020 News by InĆŖs Martins, PhD New Patent Filing for QuadraMune Relates to Potential in Aiding Memory Therapeutics Solutions InternationalĀ hasĀ announcedĀ filing a new patent covering the memory protective effects of its natural nutritional supplement QuadraMune, as seen in an animal model of memory loss caused by inflammation. QuadraMune is a nutritional supplement, available in capsule form, made of four ingredients with known anti-inflammatory, neuroprotective, and…
June 23, 2020 News by InĆŖs Martins, PhD US Court Rules in Favor of Mylan, Generic Version of Tecfidera Generic formulations of dimethyl fumarateĀ ā currently sold as Tecfidera by BiogenĀ ā were given a green light to enter the U.S. market, after a federal courtĀ invalidated a patent protecting Tecfidera from generic competition as aĀ multiple sclerosisĀ (MS) treatment.Ā The ruling by the District Court for the…
April 27, 2020 News by Joana Carvalho, PhD US Grants Patent to MedRhythmsā Proprietary Audio Engine Used in Walking Therapy Products The United States Patent and Trademark Office has issued a patent covering the intellectual rights to MedRhythmsā proprietary audio engine, a core component of the companyās rhythmic sound products designed to improve the walking ability of adult patients with multiple sclerosis (MS) and other neurological disorders. The…
January 21, 2020 News by Iqra Mumal, MSc Endonovo Therapeutics Issued Broad US Patent Covering Electromagnetic Treatment for MS The United States Patent and Trademark Office (USPTO) has issued a patent to Endonovo Therapeutics for Application No. 15/549,748, which covers the company’s technique and device for electromagnetic treatment of multiple sclerosis (MS). Endonovo has a pipeline of “Electroceuticals” ā wearable, electronic, non-invasive therapeutic devices. These devices…
January 10, 2020 News by Marisa Wexler, MS US Patent Issued for Anavex 2-73 for Treatment of Neurodevelopmental Disorders, Including MS Anavex Life Sciences has received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of several neurodegenerative and neurodevelopmental conditions, including multiple sclerosis (MS) and Rett syndrome. Issued by the U.S. Patent and Trademark Office, the new patent (no. 10,507,196) covers…
December 13, 2019 News by Marisa Wexler, MS MetP Pharma Awarded US Patent for Potential Remyelination Therapy MetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO). The patent, titled āTreatment of Demyelinating Diseasesā (U.S. Appl. No. 16/506,830), is valid until 2039,…
June 25, 2018 News by Vijaya Iyer, PhD Axim Biotech Given Patent for Method of Making Medical Cannabis Compound Axim BiotechĀ announced that its way of extracting and purifying THC (delta-9-tetrahydrocannabinol) ā an active compound in medical cannabis ā has been approved to receive a patent. The notice of allowance for patient No.Ā 15/146668Ā came in letter from the United States Patent and Trademark Office (USPTO), Axim said in…
April 12, 2018 News by Jose Marques Lopes, PhD US, Australia Issue Patents on Sonde’s Voice-analysis Technology for Diagnosing Diseases The United States and Australia have issued patents on Sonde Health‘s voice-analysis technology for diagnosing and monitoringĀ multiple sclerosisĀ and other diseases that affect speech. Sonde, which has dubbed its invention vocal biomarker technology, said the U.S. patent is Ā 9,936,914 and the Australian oneĀ 2014374349. Both patents cover Sonde’s…
January 8, 2018 News by Patricia Silva, PhD MMJ Files Patent on Part-cannabinoid and Part-non-cannabinoid Treatment for MS MMJ International HoldingsĀ is seeking a patent for a part-cannabinoid and part-non-cannabinoid treatment forĀ multiple sclerosisĀ and other diseases. The company said in aĀ news releaseĀ that it filed the patent request ahead of Phase 2 clinical trials of the formulation. Ā The therapy was developed by MMJ Bioscience, anĀ affiliate of MMJ International…
November 29, 2017 News by Patricia Silva, PhD MMJ Files US Patent for Multiple Sclerosis Cannabinoid Treatment MMJ International Holdings has applied to the U.S. Patent and Trademark Office (USPTO) for new pharmaceutical compounds and methods to treat and prevent symptoms associated with multiple sclerosis (MS) and other diseases responsive to cannabinoids. The patent covers MMJ BioScienceās intellectual property portfolio, which comprises several patent families…
November 3, 2017 News by Janet Stewart, MSc RedHill Awaits US Patent for Antibiotic Combo, RHB-104, as Potential RRMS Therapy RedHill Biopharma has received aĀ Notice of AllowanceĀ for a new patent onĀ RHB-104Ā its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States Patent and Trademark Office (USPTO),Ā this patent will be valid until 2032. RHB-104 is a proprietary, orally-administered antibiotic combinationĀ with potentially potent intracellular, antimycobacterial…
September 20, 2017 News by Alice MelĆ£o, MSc ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases The U.S. Patent and Trademark OfficeĀ has issued a patent for human embryonic stem cells derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production. This newly patented technology was developed by ImStem Biotechnology in collaboration with theĀ University of Connecticut (UConn) to advance new…
September 18, 2017 News by Patricia Silva, PhD Synthon Wins EU Patent Case Against Teva, Paving Way for Generic Copaxone for MS Patients AĀ European Patent OfficeĀ decision has opened the door toĀ SynthonĀ providing cheaper generic versions of Teva Pharmaceuticalās Copaxone to people withĀ relapsing multiple sclerosis. What looks like the final hurdle to the generics was cleared when the patent office’sĀ Technical Board of Appeal revoked the last of the patents that Teva…
April 12, 2017 News by Charles Moore Court Ruling Against 4 Patents Protecting Ampyra May Speed Arrival of Generics A ruling by the Ā U.S. District Court for the District of DelawareĀ invalidated four of five patents held by Acorda Therapeutics that pertained toĀ Ampyra (dalfampridine), a treatment for walking difficulties in multiple sclerosis (MS) patients, raising the possibility of generic forms of the drugĀ coming onto the market in a…
March 21, 2017 News by Patricia Silva, PhD Kadimastem Obtains US Patent for Neurodegenerative Disease Stem Cell Technology The United States has granted a patent toĀ Kadimastem’sĀ stem cell-based technology for treating multiple sclerosis (MS) and other diseases of the nervous system. The patent involves the technology the company used to produce supporting cells in the central nervous system derived from human stem cells, including myelin-producing cells. TheĀ United…
November 18, 2016 News by Patricia Silva, PhD AXIM Biotech to Get U.S. Patent Covering All Cannabinoids in Its Chewing Gums AXIM BiotechnologiesĀ announced that theĀ United States Patent and Trademark Office (USPTO) will be issuing a patent coveringĀ all cannabinoids ā both natural and synthetic ā Ā used in a chewing gum delivery system that may be included in itsĀ cannabinoid-containing, controlled-release chewing gum products. The USPTO has given the company aĀ Notice of…
October 26, 2016 News by Patricia Silva, PhD Medical Marijuana in the Form of Controlled-dose Capsules Now Available in New York Columbia CareĀ announced the launch of its line of pills for medical marijuana ā calling it the first controlled-dose, pharmaceutical-quality and solid-fill medical cannabinoid capsule available to people with prescriptions for medical marijuana use in the U.S. The New York State Department of Health recently approved the capsule line, in…
August 31, 2016 News by Patricia Silva, PhD RegeneRx to Receive EU Patent for Molecule That May Lead to MS Remyelination Therapy RegeneRx BiopharmaceuticalsĀ announced that it has received anĀ Intent to Grant notice from the European Patent Office (EPO) regarding a patent for itsĀ proprietary molecule Thymosin beta 4 (TĪ²4), aĀ potential therapyĀ forĀ multiple sclerosis (MS)Ā designed to promote remyelination. The patent will cover the use of TĪ²4 in a composition for treating or reducing…
August 30, 2016 News by Joana Fernandes, PhD Potential Relapsing MS Therapy, RHB-104, to Get New European Patent The European Patent Office has releasedĀ a Notice of Intention to Grant a new patent to support RHB-104 as a therapyĀ for relapsing-remitting multiple sclerosis (RRMS). RHB-104 is being developed Ā byĀ RedHill Biopharma. Patents covering the use of RHB-104 exist in over 25 countries, including the U.S., Australia, Canada, Japan, and in…
July 14, 2016 News by Patricia Silva, PhD Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS Endece wasĀ recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression. Currently in late preclinical development, NDC-1308Ā is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause…